321 related articles for article (PubMed ID: 25599347)
1. Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study.
Katz IT; Leister E; Kacanek D; Hughes MD; Bardeguez A; Livingston E; Stek A; Shapiro DE; Tuomala R
Ann Intern Med; 2015 Jan; 162(2):90-9. PubMed ID: 25599347
[TBL] [Abstract][Full Text] [Related]
2. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
3. HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa.
Myer L; Phillips TK; McIntyre JA; Hsiao NY; Petro G; Zerbe A; Ramjith J; Bekker LG; Abrams EJ
HIV Med; 2017 Feb; 18(2):80-88. PubMed ID: 27353189
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.
European Collaborative Study
Antivir Ther; 2010; 15(1):41-9. PubMed ID: 20167990
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study.
Katz IT; Shapiro R; Li D; Govindarajulu U; Thompson B; Watts DH; Hughes MD; Tuomala R
J Acquir Immune Defic Syndr; 2010 May; 54(1):27-34. PubMed ID: 20065861
[TBL] [Abstract][Full Text] [Related]
6. Mode of Delivery among HIV-Infected Pregnant Women in Philadelphia, 2005-2013.
Thompson DR; Momplaisir FM; Adams JW; Yehia BR; Anderson EA; Alleyne G; Brady KA
PLoS One; 2015; 10(12):e0144592. PubMed ID: 26657902
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with viral load suppression in HIV-infected pregnant women in Rio de Janeiro, Brazil.
Joao EC; Gouvêa MI; Menezes JA; Sidi LC; Cruz ML; Berardo PT; Ceci L; Cardoso CA; Teixeira Mde L; Calvet GA; Matos HJ
Int J STD AIDS; 2012 Jan; 23(1):44-7. PubMed ID: 22362687
[TBL] [Abstract][Full Text] [Related]
8. Low detectable postpartum viral load is associated with HIV transmission in Malawi's prevention of mother-to-child transmission programme.
Landes M; van Lettow M; Nkhoma E; Tippett Barr B; Truwah Z; Shouten E; Jahn A; Auld A; Kalua T; van Oosterhout JJ
J Int AIDS Soc; 2019 Jun; 22(6):e25290. PubMed ID: 31180186
[TBL] [Abstract][Full Text] [Related]
9. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery?
Read PJ; Mandalia S; Khan P; Harrisson U; Naftalin C; Gilleece Y; Anderson J; Hawkins DA; Taylor GP; de Ruiter A;
AIDS; 2012 Jun; 26(9):1095-103. PubMed ID: 22441248
[TBL] [Abstract][Full Text] [Related]
10. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception.
Mandelbrot L; Tubiana R; Le Chenadec J; Dollfus C; Faye A; Pannier E; Matheron S; Khuong MA; Garrait V; Reliquet V; Devidas A; Berrebi A; Allisy C; Elleau C; Arvieux C; Rouzioux C; Warszawski J; Blanche S;
Clin Infect Dis; 2015 Dec; 61(11):1715-25. PubMed ID: 26197844
[TBL] [Abstract][Full Text] [Related]
11. Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women.
Kowalska A; Niemiec T; El Midaoui A; Burkacka E
Med Wieku Rozwoj; 2003; 7(4 Pt 1):459-68. PubMed ID: 15010556
[TBL] [Abstract][Full Text] [Related]
12. [Factors associated with virological response in women receiving highly-active antiretroviral prophylaxis for HIV-1 mother-to-child transmission].
Palacios R; Senise JF; Vaz MJ; Castelo A
Enferm Infecc Microbiol Clin; 2008; 26(7):411-5. PubMed ID: 18842235
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women.
McCabe CJ; Goldie SJ; Fisman DN
PLoS One; 2010 Apr; 5(4):e10154. PubMed ID: 20405011
[TBL] [Abstract][Full Text] [Related]
14. Maternal HIV viral load testing during pregnancy and postpartum care in Gauteng Province, South Africa.
Moyo F; Mazanderani AH; Kufa T; Sherman GG
S Afr Med J; 2021 Apr; 111(5):469-473. PubMed ID: 34852890
[TBL] [Abstract][Full Text] [Related]
15. Viral suppression and factors associated with failure to achieve viral suppression among pregnant women in South Africa.
Woldesenbet SA; Kufa T; Barron P; Chirombo BC; Cheyip M; Ayalew K; Lombard C; Manda S; Diallo K; Pillay Y; Puren AJ
AIDS; 2020 Mar; 34(4):589-597. PubMed ID: 31821189
[TBL] [Abstract][Full Text] [Related]
16. Short communication: Use of raltegravir in late-presenting HIV-infected pregnant women.
Nóbrega I; Travassos AG; Haguihara T; Amorim F; Brites C
AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1451-4. PubMed ID: 23731224
[TBL] [Abstract][Full Text] [Related]
17. Prevention of mother-to-child HIV transmission: similar access for sub-Sahara African immigrants and for French women?
Jasseron C; Mandelbrot L; Tubiana R; Teglas JP; Faye A; Dollfus C; Le Chenadec J; Rouzioux C; Blanche S; Warszawski J;
AIDS; 2008 Jul; 22(12):1503-11. PubMed ID: 18614874
[TBL] [Abstract][Full Text] [Related]
18. Optimizing prevention of HIV mother to child transmission: Duration of antiretroviral therapy and viral suppression at delivery among pregnant Malawian women.
Chagomerana MB; Miller WC; Tang JH; Hoffman IF; Mthiko BC; Phulusa J; John M; Jumbe A; Hosseinipour MC
PLoS One; 2018; 13(4):e0195033. PubMed ID: 29614083
[TBL] [Abstract][Full Text] [Related]
19. Same-day antiretroviral therapy (ART) initiation in pregnancy is not associated with viral suppression or engagement in care: A cohort study.
Langwenya N; Phillips TK; Brittain K; Zerbe A; Abrams EJ; Myer L
J Int AIDS Soc; 2018 Jun; 21(6):e25133. PubMed ID: 29939483
[TBL] [Abstract][Full Text] [Related]
20. High viral load and elevated angiogenic markers associated with increased risk of preeclampsia among women initiating highly active antiretroviral therapy in pregnancy in the Mma Bana study, Botswana.
Powis KM; McElrath TF; Hughes MD; Ogwu A; Souda S; Datwyler SA; von Widenfelt E; Moyo S; Nádas M; Makhema J; Machakaire E; Lockman S; Essex M; Shapiro RL
J Acquir Immune Defic Syndr; 2013 Apr; 62(5):517-24. PubMed ID: 23344545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
